Clinical Trials Logo

Clinical Trial Summary

This proposed study will evaluate the efficacy and safety of preoperative administration Sintilimab combined with nab-paclitaxel and carboplatin in salivary gland malignant neoplasms who are about to undergo surgery. Monoclonal antibodies, such as Sintilimab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will be helpful for comprehensive exploratory characterization of tumor immune microenvironment and circulating immune cells in these patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05000892
Study type Interventional
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Song Fan, Doctor degrees
Phone 020-81332477
Email fansong2@mail.asysu.edu.cn
Status Recruiting
Phase Phase 2
Start date December 10, 2021
Completion date October 1, 2027

See also
  Status Clinical Trial Phase
Completed NCT02921984 - Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors Phase 1
Recruiting NCT05601401 - Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2 Phase 2
Recruiting NCT02776163 - Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors Phase 2
Not yet recruiting NCT04825938 - Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms Phase 2